629 related articles for article (PubMed ID: 28052011)
1. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
2. The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.
Alzrigat M; Jernberg-Wiklund H
RNA Dis; 2017; 4(2):. PubMed ID: 28664185
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
4. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
5. Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma.
Wu C; Ruan T; Liu W; Zhu X; Pan J; Lu W; Yan C; Tao K; Zhang W; Zhang C
Curr Pharm Des; 2018; 24(5):564-575. PubMed ID: 28322158
[TBL] [Abstract][Full Text] [Related]
6. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
7. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
Herviou L; Cavalli G; Moreaux J
Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
[TBL] [Abstract][Full Text] [Related]
8. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
Licht JD
Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
[TBL] [Abstract][Full Text] [Related]
9. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T; Dupéré-Richer D; Will CM; Small EC; Varghese N; Patel T; Nabet B; Popovic R; Oyer J; Bulic M; Zheng Y; Huang X; Shah MY; Maji S; Riva A; Occhionorelli M; Tonon G; Kelleher N; Keats J; Licht JD
Cell Rep; 2017 Oct; 21(3):628-640. PubMed ID: 29045832
[TBL] [Abstract][Full Text] [Related]
10. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis.
Ihira K; Dong P; Xiong Y; Watari H; Konno Y; Hanley SJ; Noguchi M; Hirata N; Suizu F; Yamada T; Kudo M; Sakuragi N
Oncotarget; 2017 Feb; 8(8):13509-13520. PubMed ID: 28088786
[TBL] [Abstract][Full Text] [Related]
12. A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma.
Nylund P; Atienza Párraga A; Haglöf J; De Bruyne E; Menu E; Garrido-Zabala B; Ma A; Jin J; Öberg F; Vanderkerken K; Kalushkova A; Jernberg-Wiklund H
Cell Death Dis; 2021 Feb; 12(2):167. PubMed ID: 33579905
[TBL] [Abstract][Full Text] [Related]
13. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.
Rastgoo N; Pourabdollah M; Abdi J; Reece D; Chang H
Leukemia; 2018 Nov; 32(11):2471-2482. PubMed ID: 29743723
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
16. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
[TBL] [Abstract][Full Text] [Related]
17.
Nylund P; Garrido-Zabala B; Párraga AA; Vasquez L; Pyl PT; Harinck GM; Ma A; Jin J; Öberg F; Kalushkova A; Wiklund HJ
Haematologica; 2024 Feb; 109(2):567-577. PubMed ID: 37496441
[TBL] [Abstract][Full Text] [Related]
18. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
19. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
[TBL] [Abstract][Full Text] [Related]
20. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma.
Wang L; Zhang X; Jia LT; Hu SJ; Zhao J; Yang JD; Wen WH; Wang Z; Wang T; Zhao J; Wang RA; Meng YL; Nie YZ; Dou KF; Chen SY; Yao LB; Fan DM; Zhang R; Yang AG
Hepatology; 2014 May; 59(5):1850-63. PubMed ID: 24002871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]